Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.77 USD
Change Today +0.02 / 0.73%
Volume 21.7K
As of 2:37 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

cymabay therapeutics inc (CBAY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/9/14 - $13.78
52 Week Low
06/30/15 - $2.64
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cymabay therapeutics inc (CBAY) Related Businessweek News

No Related Businessweek News Found

cymabay therapeutics inc (CBAY) Details

Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company’s product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.

18 Employees
Last Reported Date: 05/11/15
Founded in 1988

cymabay therapeutics inc (CBAY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $800.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $480.0K
Chief Medical Officer
Total Annual Compensation: $439.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $366.0K
Compensation as of Fiscal Year 2014.

cymabay therapeutics inc (CBAY) Key Developments

Cymabay Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 10:00 AM

Cymabay Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Cymabay Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Cymabay Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s net loss was $2.3 million compared to $10.1 million for three months ended March 31, 2014. The difference in net loss between these periods was primarily due to a non- cash gain of $4.6 million for the three months ended March 31, 2015 compared to a non-cash loss of $4.8 million for the three months ended March 31, 2014, from the mark to market valuation of CymaBay's warrant liability. Loss from operations was $6,776,000 compared to $5,115,000 a year ago. Diluted net loss per common share was $0.44 compared to $1.02 a year ago.

Cymabay Therapeutics, Inc. to Report Q1, 2015 Results on May 07, 2015

Cymabay Therapeutics, Inc. announced that they will report Q1, 2015 results on May 07, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBAY:US $2.77 USD +0.02

CBAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBAY.
View Industry Companies

Industry Analysis


Industry Average

Valuation CBAY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYMABAY THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at